Cogent Biosciences, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Cogent Biosciences, Inc. (COGT) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $551.30 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $551.30M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $428.70M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $40.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $14.60M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $551.30M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $428.70M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $40.00M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $14.60M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $68.30M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $8.90M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $8.90M 10-K · filed 2026-02-17 |
| 2024-06-30 | $302.90M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $158.30M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $34.70M 10-K · filed 2025-02-25 |
| 2023-09-30 | $206.10M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $92.10M 10-Q · filed 2023-08-08 |
| 2022-12-31 | $99.50M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |